Introduction : Cardiovascular disease (CVD) remains a leading cause of mortality worldwide, emphasizing the need for effective prevention and management strategies
The combination was well tolerated but an additional arm of the study that involve triple therapy (garetosmab (anti-activin A) was generally not
Notably, the median PA time of ~6 days (for cases needing extra review) means many patients wait well over a week to start treatment ( [5] )
This article explores early warning Read More Counseling Patients on Emerging GLP-1 Benefits: How to Balance Evidence and Expectations Apr 27, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Type 2 Diabetes, Type 2 Diabetes 2,986 views Patients today are more informed than ever, but are they always getting the full picture
Unlike some compounded regimens that allow for flexible or micro-dosed schedules, FDA-approved GLP-1s have specific dosing timelines (usually weekly)
What the Phase 2 Data Shows The retatrutide Phase 2 obesity trial (Jastreboff et al., New England Journal of Medicine , 2023) is the primary published source for quantifying the heart rate effect
